Effects of Tirzepatide Versus Basal Insulins in People With Type 2 Diabetes and Different Baseline Glycemic Patterns: Post Hoc Analyses of the SURPASS-3 and SURPASS-4 Trials.

Giorgino F, Franco DR, Nicolay C, Hemmingway A, Rodríguez Á, Wiese RJ

Diabetes care1 Jun 2024Cited by 3 (Europe PMC)

PMID38530948PMCIDPMC11116914DOI10.2337/dc23-2366PepBankPUB-38530948

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study7

7 results from studies that gave the peptide. 7 results from people.

01HumanRandomized controlled trialEfficacy outcome
In adults with type 2 diabetes, all tirzepatide doses decreased HbA1c from baseline to week 52 in all fasting and postprandial glucose subgroups.
In plain wordsIn adults with type 2 diabetes, HbA1c fell with every tirzepatide dose, in every glucose-pattern group.
Peptide
Tirzepatide
Outcome
DecreaseHbA1c change from baseline to week 52, all glycemic-pattern subgroups
Study
n: not reported in source
Outcome group
Glycemic control · Metabolic and weight
Studied dose
5, 10, 15 mg · 52 weeksAs given in this study (human).
Source sentences
Summary
All tirzepatide doses and basal insulins were associated with decreased HbA1c, FSG, and PPG values from baseline to week 52 in all subgroups (P < 0.05).
2 context sentences(design, population, supporting numbers)
Summary · context
This post hoc analysis assessed change from baseline to week 52 in glycemic parameters for tirzepatide (5, 10, 15 mg) versus insulin degludec (SURPASS-3 trial) and glargine (SURPASS-4 trial) in people with type 2 diabetes and different baseline glycemic patterns, based on fasting serum glucose (FSG)…
Summary · context
Participant subgroups with low FSG/low PPG, low FSG/high PPG, high FSG/low PPG, and high FSG/high PPG were defined according to the median values of these measures.
Report a problemFND-3853094801
02HumanRandomized controlled trialEfficacy outcome
In adults with type 2 diabetes, all tirzepatide doses decreased fasting serum glucose from baseline to week 52 in all subgroups.
In plain wordsIn adults with type 2 diabetes, fasting blood sugar fell with every tirzepatide dose, in every glucose-pattern group.
Peptide
Tirzepatide
Outcome
DecreaseFasting serum glucose change from baseline to week 52, all subgroups
Study
n: not reported in source
Outcome group
Glycemic control · Metabolic and weight
Studied dose
5, 10, 15 mg · 52 weeksAs given in this study (human).
Source sentences
Summary
All tirzepatide doses and basal insulins were associated with decreased HbA1c, FSG, and PPG values from baseline to week 52 in all subgroups (P < 0.05).
2 context sentences(design, population, supporting numbers)
Summary · context
This post hoc analysis assessed change from baseline to week 52 in glycemic parameters for tirzepatide (5, 10, 15 mg) versus insulin degludec (SURPASS-3 trial) and glargine (SURPASS-4 trial) in people with type 2 diabetes and different baseline glycemic patterns, based on fasting serum glucose (FSG)…
Summary · context
Participant subgroups with low FSG/low PPG, low FSG/high PPG, high FSG/low PPG, and high FSG/high PPG were defined according to the median values of these measures.
Report a problemFND-3853094802
03HumanRandomized controlled trialEfficacy outcome
In adults with type 2 diabetes, all tirzepatide doses decreased postprandial glucose from baseline to week 52 in all subgroups.
In plain wordsIn adults with type 2 diabetes, blood sugar after meals fell with every tirzepatide dose, in every glucose-pattern group.
Peptide
Tirzepatide
Outcome
DecreasePostprandial glucose change from baseline to week 52, all subgroups
Study
n: not reported in source
Outcome group
Glycemic control · Metabolic and weight
Studied dose
5, 10, 15 mg · 52 weeksAs given in this study (human).
Source sentences
Summary
All tirzepatide doses and basal insulins were associated with decreased HbA1c, FSG, and PPG values from baseline to week 52 in all subgroups (P < 0.05).
2 context sentences(design, population, supporting numbers)
Summary · context
This post hoc analysis assessed change from baseline to week 52 in glycemic parameters for tirzepatide (5, 10, 15 mg) versus insulin degludec (SURPASS-3 trial) and glargine (SURPASS-4 trial) in people with type 2 diabetes and different baseline glycemic patterns, based on fasting serum glucose (FSG)…
Summary · context
Participant subgroups with low FSG/low PPG, low FSG/high PPG, high FSG/low PPG, and high FSG/high PPG were defined according to the median values of these measures.
Report a problemFND-3853094803
04HumanRandomized controlled trialEfficacy outcome
In adults with type 2 diabetes, HbA1c decreases were greater with tirzepatide than with basal insulin within each glycemic-pattern subgroup.
In plain wordsIn adults with type 2 diabetes, HbA1c fell more with tirzepatide than with basal insulin in every glucose-pattern group.
Peptide
Tirzepatide
Outcome
DecreaseHbA1c decrease, tirzepatide versus basal insulin, within subgroups
Study
n: not reported in source
Comparator
Insulin degludec or glargine
Outcome group
Glycemic control · Metabolic and weight
Studied dose
5, 10, 15 mg · 52 weeksAs given in this study (human).
Source sentences
Summary
Within each subgroup, HbA1c and PPG decreases were greater with tirzepatide than insulin (P < 0.05).
2 context sentences(design, population, supporting numbers)
Summary · context
This post hoc analysis assessed change from baseline to week 52 in glycemic parameters for tirzepatide (5, 10, 15 mg) versus insulin degludec (SURPASS-3 trial) and glargine (SURPASS-4 trial) in people with type 2 diabetes and different baseline glycemic patterns, based on fasting serum glucose (FSG)…
Summary · context
Participant subgroups with low FSG/low PPG, low FSG/high PPG, high FSG/low PPG, and high FSG/high PPG were defined according to the median values of these measures.
Report a problemFND-3853094804
05HumanRandomized controlled trialEfficacy outcome
In adults with type 2 diabetes, postprandial glucose decreases were greater with tirzepatide than with basal insulin within each glycemic-pattern subgroup.
In plain wordsIn adults with type 2 diabetes, blood sugar after meals fell more with tirzepatide than with basal insulin in every glucose-pattern group.
Peptide
Tirzepatide
Outcome
DecreasePostprandial glucose decrease, tirzepatide versus basal insulin, within subgroups
Study
n: not reported in source
Comparator
Insulin degludec or glargine
Outcome group
Glycemic control · Metabolic and weight
Studied dose
5, 10, 15 mg · 52 weeksAs given in this study (human).
Source sentences
Summary
Within each subgroup, HbA1c and PPG decreases were greater with tirzepatide than insulin (P < 0.05).
2 context sentences(design, population, supporting numbers)
Summary · context
This post hoc analysis assessed change from baseline to week 52 in glycemic parameters for tirzepatide (5, 10, 15 mg) versus insulin degludec (SURPASS-3 trial) and glargine (SURPASS-4 trial) in people with type 2 diabetes and different baseline glycemic patterns, based on fasting serum glucose (FSG)…
Summary · context
Participant subgroups with low FSG/low PPG, low FSG/high PPG, high FSG/low PPG, and high FSG/high PPG were defined according to the median values of these measures.
Report a problemFND-3853094805
06HumanRandomized controlled trialEfficacy outcome
In adults with type 2 diabetes, fasting serum glucose decreases were generally similar between tirzepatide and basal insulin.
In plain wordsIn adults with type 2 diabetes, fasting blood sugar fell by a similar amount with tirzepatide and with basal insulin.
Peptide
Tirzepatide
Outcome
No significant changeFasting serum glucose decrease, tirzepatide versus basal insulin
Study
n: not reported in source
Comparator
Insulin degludec or glargine
Outcome group
Glycemic control · Metabolic and weight
Studied dose
5, 10, 15 mg · 52 weeksAs given in this study (human).
Source sentences
Summary
FSG decreases were generally similar.
2 context sentences(design, population, supporting numbers)
Summary · context
This post hoc analysis assessed change from baseline to week 52 in glycemic parameters for tirzepatide (5, 10, 15 mg) versus insulin degludec (SURPASS-3 trial) and glargine (SURPASS-4 trial) in people with type 2 diabetes and different baseline glycemic patterns, based on fasting serum glucose (FSG)…
Summary · context
Participant subgroups with low FSG/low PPG, low FSG/high PPG, high FSG/low PPG, and high FSG/high PPG were defined according to the median values of these measures.
Report a problemFND-3853094806
07HumanRandomized controlled trialEfficacy outcome
In adults with type 2 diabetes, there were no differential effects of tirzepatide versus basal insulin across the fasting and postprandial glucose subgroups.
In plain wordsIn adults with type 2 diabetes, the advantage of tirzepatide over basal insulin did not depend on the starting glucose pattern.
Peptide
Tirzepatide
Outcome
No significant changeDifferential treatment effect by fasting and postprandial glucose subgroup
Study
n: not reported in source
Comparator
Insulin degludec or glargine
Outcome group
Glycemic control · Metabolic and weight
Studied dose
5, 10, 15 mg · 52 weeksAs given in this study (human).
Source sentences
Summary
There were no differential treatment effects by FSG/PPG subgroup.
2 context sentences(design, population, supporting numbers)
Summary · context
This post hoc analysis assessed change from baseline to week 52 in glycemic parameters for tirzepatide (5, 10, 15 mg) versus insulin degludec (SURPASS-3 trial) and glargine (SURPASS-4 trial) in people with type 2 diabetes and different baseline glycemic patterns, based on fasting serum glucose (FSG)…
Summary · context
Participant subgroups with low FSG/low PPG, low FSG/high PPG, high FSG/low PPG, and high FSG/high PPG were defined according to the median values of these measures.
Report a problemFND-3853094807

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
12 Oct 2026, 12:58 UTC
Study results updated
Version 1
9 Oct 2026, 03:07 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

PepBank is a research reference. Talk to a doctor before you use any peptide.